Safety and Efficacy of Lebrikizumab for Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
N. Engl. J. Med 2023 Mar 23;388(12)1080-1091, JI Silverberg, E Guttman-Yassky, D Thaçi, AD Irvine, L Stein Gold, A Blauvelt, EL Simpson, CY Chu, Z Liu, R Gontijo Lima, SG Pillai, J SeneschalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.